Plus Therapeutics Inc
Veridion Score
BETALOW CONF · 4 of 6 factors measuredComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is CNSY moving today?
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
CNSY overview
Related filings and maps
Congress activity in CNSY
No receipt-qualified Congressional disclosure is present for CNSY in the cached public ledger.
CNSY contract awards, year to date.
Public federal awards linked to this ticker.
CNSY lobbying filings, year to date.
Registered lobbying filings matched to Plus Therapeutics Inc.